| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Exploring Opportunities in the Electric Vehicle Space.
For 25+ years, MIRACORP has served government and commercial clients. SMALL BUSINESS DESIGNATIONS -100% Woman-owned (WOSB) GSA Schedules: MAS - 47QSHA20D000Z NAICS CODE SERIES 541 - Professional, Scientific, Technical and Administrative Services 561 - Administrative and Facilities Support 611 - Educational Services
Dedicated to assisting organizations leverage value from their most significant and least understood asset - their data.
The "Technology Innovation Studio (TINS)" is a physical space at the Cambridge Innovation Center (CIC) in Kendall Square that brings together business leaders, scientists and researchers, serial entrepreneurs, angel/VC investors, industry experts, corporate innovation teams and also policy experts to explore and apply tools, methods and models in innovation.